Minimizing radiation exposure in very preterm babies

Lung Ultrasound to Reduce the Number of Chest X-rays in Very Preterm Infants in the First 2 Weeks After Birth: A Randomised Controlled Trial

Phase 2 Interventional Western Health, Australia · NCT06975189

This trial will try using bedside lung ultrasound instead of routine chest X-rays to guide breathing support for babies born before 32 weeks.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment180 (estimated)
AgesN/A to 24 Hours
SexAll
SponsorWestern Health, Australia Government
Drugs / interventionsradiation
Locations1 site (Melbourne, Victoria)
Trial IDNCT06975189 on ClinicalTrials.gov

What this trial studies

This phase 2 interventional trial compares care guided by lung ultrasound with standard care that relies on chest X-rays in very preterm infants. Eligible infants (22 to 31+6 weeks' gestation) admitted to the NICU who require lung imaging will be enrolled with parental consent and allocated to either the lung ultrasound group or standard care. Lung ultrasound is radiation-free and can be performed at the bedside to provide more frequent, real-time information about lung status. The study will measure radiation exposure and short-term respiratory management outcomes while monitoring safety and tolerability.

Who should consider this trial

Good fit: Infants born between 22 and 31+6 weeks' gestation who are admitted to the NICU, require lung imaging for respiratory reasons, and have a parent or guardian able to give informed consent are ideal candidates.

Not a fit: Babies who only need chest X-rays for non-respiratory reasons (such as device placement or cardiac assessment), or those whose skin or clinical stability prevents ultrasound, are unlikely to benefit from the intervention.

Why it matters

Potential benefit: If successful, this approach could substantially reduce radiation exposure and provide faster, bedside lung monitoring that helps tailor breathing support.

How similar studies have performed: Observational and pilot studies suggest lung ultrasound is promising in neonates, but few randomized trials have been completed to confirm benefit and safety.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

All infants born \<32 weeks' gestation and admitted to the neonatal intensive care unit (NICU) who require lung imaging for respiratory indications will be considered eligible. Each infant must meet all the following criteria to be enrolled in this study:

* The infant is born from 22 to 31+6 weeks' gestation by best obstetric estimate and admitted to the NICU
* The infant is considered to require lung imaging for respiratory indications
* The infant has a parent/guardian who can provide informed consent.

Exclusion Criteria

* The infant will only require CXR to be performed solely to confirm device position i.e. central line, endotracheal tube, gastric tubes
* The infant will only require CXR to be performed for specifically for non-respiratory indications i.e. assessment of cardiac silhouette
* The infant's Clinician has concern regarding clinical stability and tolerability of ultrasound scans
* The infant's skin integrity will not tolerate ultrasound gel
* Refusal of informed consent by their parent/guardian/legally acceptable representative
* The infant does not have a parent/guardian who can provide informed consent.

Where this trial is running

Melbourne, Victoria

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Neonatal Respiratory Distress SyndromePreTerm NeonateLung ultrasoundRespiratory Distress SyndromePrematurity
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.